Tuberculosis diagnosis by BCG inoculation tuberculin tests can be affected. In general the US approach is likely to result in more false positives and more unnecessary treatment with potentially toxic drugs; the UK approach is as sensitive in theory and should also be more specific, because of the use of interferon-γ tests. Under the US recommendations, diagnosis and treatment of latent tuberculosis infection (LTBI) is considered for any BCG-vaccinated person whose skin test is 10 mm or greater, if any of these circumstances are present: These have been reviewed in detail. In 2007, a systematic review of adenosine deaminase by the NHS
BCG disease outbreak in Finland in the 2000s In practice, however, almost everything that's connected to vaccines is done with the National Public Health Institute. NPHI also does significant research funded by outside sources - ca. 40% of funding is outside, and the policy is to get as much outside funding as possible. Among the biggest funders has been the vaccine giant GlaxoSmithKline between 2003 and 2005. In the 1970s, there was a similar outbreak of BCG osteitis osteomyelitis in some Nordic countries, Sweden and Finland, when a Swedish-Danish BCG vaccine strain was used. To resolve the issue, Sweden discontinued mass BCG vaccinations to newborns, and Finland switched